ImmunoGen (NASDAQ:IMGN) reported Q1 2018 earnings this Morning, coming in at ($0.30) per share, missing Wall Street’s estimates of ($0.24) per Share. Revenue for the quarter came in at $19.80 million beating analyst estimates of $15.04 million Recent Insider Trading for ImmunoGen (NASDAQ:IMGN)
- On 3/16/2018 Daniel M Junius, Director, sold 25,000 with an average share price of $12.02 per share and the total transaction amounting to $300,500.00.
- On 3/15/2018 David Brannon Johnston, CFO, sold 10,000 with an average share price of $11.53 per share and the total transaction amounting to $115,300.00.
- On 2/21/2018 David Brannon Johnston, CFO, sold 21,060 with an average share price of $10.87 per share and the total transaction amounting to $228,922.20.
- On 2/21/2018 Mark J Enyedy, CEO, sold 67,717 with an average share price of $10.87 per share and the total transaction amounting to $736,083.79.
- On 2/21/2018 Richard J Gregory, VP, sold 34,486 with an average share price of $10.88 per share and the total transaction amounting to $375,207.68.
- On 2/20/2018 Daniel M Junius, Director, sold 25,000 with an average share price of $11.68 per share and the total transaction amounting to $292,000.00.
Dividend History for ImmunoGen (NASDAQ:IMGN)
Recent Trading for ImmunoGen (NASDAQ:IMGN) Shares of ImmunoGen closed the previous trading session at 10.65 down -0.35 3.21% with 10.260000228881836 shares trading hands.